Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Income from Continuing Operations: 2023-2024

Historic Income from Continuing Operations for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to -$14.6 million.

  • Contineum Therapeutics' Income from Continuing Operations fell 87.48% to -$14.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$42.3 million, marking a year-over-year decrease of 285.94%. This contributed to the annual value of -$42.3 million for FY2024, which is 285.99% down from last year.
  • Latest data reveals that Contineum Therapeutics reported Income from Continuing Operations of -$14.6 million as of Q4 2024, which was down 41.86% from -$10.3 million recorded in Q3 2024.
  • Over the past 5 years, Contineum Therapeutics' Income from Continuing Operations peaked at $41.6 million during Q2 2023, and registered a low of -$14.6 million during Q4 2024.
  • Its 2-year average for Income from Continuing Operations is -$2.4 million, with a median of -$8.1 million in 2023.
  • Data for Contineum Therapeutics' Income from Continuing Operations shows a maximum YoY plummeted of 121.67% (in 2024) over the last 5 years.
  • Over the past 2 years, Contineum Therapeutics' Income from Continuing Operations (Quarterly) stood at -$7.8 million in 2023, then crashed by 87.48% to -$14.6 million in 2024.
  • Its Income from Continuing Operations was -$14.6 million in Q4 2024, compared to -$10.3 million in Q3 2024 and -$9.0 million in Q2 2024.